A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 4532-4532 ◽  
Author(s):  
E. S. Antonarakis ◽  
E. I. Heath ◽  
D. C. Smith ◽  
D. E. Rathkopf ◽  
A. L. Blackford ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Randomized Phase Ii ◽  
Dose Levels

Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel

2014 ◽  
Vol 25 (9) ◽  
pp. 1081-1088 ◽  
Author(s):  
Jean-Pierre Droz ◽  
Jaques Medioni ◽  
Christine Chevreau ◽  
Helene De Mont-Serrat ◽  
Michael Merger ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Randomized Phase Ii

scholarly journals A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209

Oncotarget ◽  
2018 ◽  
Vol 9 (8) ◽  
pp. 8155-8164 ◽  
Author(s):  
Bernhard Josef Eigl ◽  
Kim Chi ◽  
Dongsheng Tu ◽  
Sebastien J. Hotte ◽  
Eric Winquist ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Randomized Phase Ii
Sign in / Sign up

Export Citation Format

Share Document